OP0244-PARE Determining the Barriers for Medicine Application in Patients with RA in Macedonia
| Autor: | V. Ognenovski, N. Bogdanovska, I. Hadji Mitova, D. Chichikj |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Enthusiasm
medicine.medical_specialty Government Traditional medicine Package insert business.industry media_common.quotation_subject Immunology General Biochemistry Genetics and Molecular Biology Insider Rheumatology Telephone interview Family medicine Health care Immunology and Allergy Medicine Medical history business media_common Patient education |
| Zdroj: | Annals of the Rheumatic Diseases. 74:164.1-164 |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2015-eular.4599 |
| Popis: | Background Macedonia has a social healthcare lagging behind all European countries (1). Patients with RA have average DAS28 of ∼5.2, one of the highest in Europe (2,3). The government funding is limited, only ∼$730K/y is allotted for medicines for patients with RMDs. There is a centralized access; no rheumatologists outside the capital. The average dose of MTX is Objectives The research aims to determine barriers for therapy application. The research outputs serve for legal policy development aimed for the institutions & medical community, i.e. strategic nationwide solutions; helps us identify other patients9 needs. Methods We conducted a quantitative research survey with a representative sample of 200 patients with RA, via scheduled ∼40 min. telephone interview of 50 questions in 6 chapters: demographics, diagnosis, therapy, logistics, doctor-patient relations & other. Candidates were pre-screened for enrollment, i.e. fulfilling the requirements for disease longevity, demographic, medical history, and other factors which the research takes as necessary. The participants were randomly selected from a database of ∼500 RA patients demographically evenly distributed. Results are analyzed by a non-bias third-party analyst. Results In Macedonia, this was a first study of the perceptions & experiences of RA patients about the therapy. Results show that education about medicines is one of the unmet patient needs; 27% answered that they would like more education about their condition & medicines. 39% answered that in some degree they are afraid from the side effects of the medicines, i.e. pointing out that the medicine package insert is often their only means of information about the medicines. Conclusions The lack of medicine may be the biggest barrier, e.g. less available therapy poses difficulty acquiring it, leading to fewer choices, poorer treatment options and outcomes, thus lower patient enthusiasm and interest for its use. Education about medicines, i.e. understanding how they work, their delayed effects & side effects, are also a barrier. Other barriers: patients9 financial burden, travel, insufficient doctor-patient relations & appointment time; poor healthcare, centralization, etc. The research provided other significant data being analyzed. The research helped us identify education programs & projects, e.g. in Jan. 2015, we were awarded a $13.900US grant by ILAR, to publish, print and disseminate material nationwide for patient education on medicines. References Business Insider/Numbeo: http://goo.gl/OF8Vj0 Sokka T. et al. Ann Rheum Dis (2007) 66:1491–1496 Ognenovski, V. et al. ILAR Clin Rheumatol (2013) 32:1669-1671 Putrik, P. A&R (2012) vol. 64, Abstract Supplement Disclosure of Interest None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|